CTU: A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02).

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleDB-1303-O-3002
AcronymDYNASTY-Breast02
StatusActive
Effective start/end date20/02/24 → 16/11/28